9 results on '"Graham, Barney S."'
Search Results
2. Rational Design of an Epstein-Barr Virus Vaccine Targeting the Receptor-Binding Site.
- Author
-
Kanekiyo, Masaru, Bu, Wei, Joyce, M. Gordon, Meng, Geng, Whittle, James R.R., Baxa, Ulrich, Yamamoto, Takuya, Narpala, Sandeep, Todd, John-Paul, Rao, Srinivas S., McDermott, Adrian B., Koup, Richard A., Rossmann, Michael G., Mascola, John R., Graham, Barney S., Cohen, Jeffrey I., and Nabel, Gary J.
- Subjects
- *
EPSTEIN-Barr virus , *VIRAL vaccines , *TARGETED drug delivery , *BINDING sites , *CELL receptors - Abstract
Summary Epstein-Barr virus (EBV) represents a major global health problem. Though it is associated with infectious mononucleosis and ∼200,000 cancers annually worldwide, a vaccine is not available. The major target of immunity is EBV glycoprotein 350/220 (gp350) that mediates attachment to B cells through complement receptor 2 (CR2/CD21). Here, we created self-assembling nanoparticles that displayed different domains of gp350 in a symmetric array. By focusing presentation of the CR2-binding domain on nanoparticles, potent neutralizing antibodies were elicited in mice and non-human primates. The structurally designed nanoparticle vaccine increased neutralization 10- to 100-fold compared to soluble gp350 by targeting a functionally conserved site of vulnerability, improving vaccine-induced protection in a mouse model. This rational approach to EBV vaccine design elicited potent neutralizing antibody responses by arrayed presentation of a conserved viral entry domain, a strategy that can be applied to other viruses. PaperClip [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
3. Structural Basis for Potent Neutralization of Betacoronaviruses by Single-Domain Camelid Antibodies.
- Author
-
Wrapp, Daniel, De Vlieger, Dorien, Corbett, Kizzmekia S., Torres, Gretel M., Wang, Nianshuang, Van Breedam, Wander, Roose, Kenny, van Schie, Loes, Hoffmann, Markus, Pöhlmann, Stefan, Graham, Barney S., Callewaert, Nico, Schepens, Bert, Saelens, Xavier, and McLellan, Jason S.
- Subjects
- *
CELL receptors , *SARS-CoV-2 , *COVID-19 , *IMMUNOGLOBULINS , *MEMBRANE fusion , *BETACORONAVIRUS - Abstract
Coronaviruses make use of a large envelope protein called spike (S) to engage host cell receptors and catalyze membrane fusion. Because of the vital role that these S proteins play, they represent a vulnerable target for the development of therapeutics. Here, we describe the isolation of single-domain antibodies (VHHs) from a llama immunized with prefusion-stabilized coronavirus spikes. These VHHs neutralize MERS-CoV or SARS-CoV-1 S pseudotyped viruses, respectively. Crystal structures of these VHHs bound to their respective viral targets reveal two distinct epitopes, but both VHHs interfere with receptor binding. We also show cross-reactivity between the SARS-CoV-1 S-directed VHH and SARS-CoV-2 S and demonstrate that this cross-reactive VHH neutralizes SARS-CoV-2 S pseudotyped viruses as a bivalent human IgG Fc-fusion. These data provide a molecular basis for the neutralization of pathogenic betacoronaviruses by VHHs and suggest that these molecules may serve as useful therapeutics during coronavirus outbreaks. • VHHs isolated from a llama immunized with prefusion-stabilized coronavirus spikes • Structural characterization of VHHs reveals conserved mechanism of neutralization • SARS-CoV-1 S-directed VHH cross-reacts with SARS-CoV-2 S • Bivalent VHH neutralizes SARS-CoV-2 pseudoviruses Using llamas immunized with prefusion-stabilized betacoronavirus spike proteins, Wrapp et al. identify neutralizing cross-reactive single-domain camelid antibodies, which may serve not only as useful reagents for researchers studying the viruses causing MERS, SARS, and COVID-19, but also potential therapeutic candidates. Crystal structures further reveal how these antibodies bind spike proteins to prevent virus entry into cells. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
4. High-Throughput Mapping of B Cell Receptor Sequences to Antigen Specificity.
- Author
-
Setliff, Ian, Shiakolas, Andrea R., Pilewski, Kelsey A., Murji, Amyn A., Mapengo, Rutendo E., Janowska, Katarzyna, Richardson, Simone, Oosthuysen, Charissa, Raju, Nagarajan, Ronsard, Larance, Kanekiyo, Masaru, Qin, Juliana S., Kramer, Kevin J., Greenplate, Allison R., McDonnell, Wyatt J., Graham, Barney S., Connors, Mark, Lingwood, Daniel, Acharya, Priyamvada, and Morris, Lynn
- Subjects
- *
B cell receptors , *ANTIGEN receptors , *HIV antibodies , *B cells , *IMMUNE response , *VACCINE effectiveness - Abstract
B cell receptor (BCR) sequencing is a powerful tool for interrogating immune responses to infection and vaccination, but it provides limited information about the antigen specificity of the sequenced BCRs. Here, we present LIBRA-seq (linking B cell receptor to antigen specificity through sequencing), a technology for high-throughput mapping of paired heavy- and light-chain BCR sequences to their cognate antigen specificities. B cells are mixed with a panel of DNA-barcoded antigens so that both the antigen barcode(s) and BCR sequence are recovered via single-cell next-generation sequencing. Using LIBRA-seq, we mapped the antigen specificity of thousands of B cells from two HIV-infected subjects. The predicted specificities were confirmed for a number of HIV- and influenza-specific antibodies, including known and novel broadly neutralizing antibodies. LIBRA-seq will be an integral tool for antibody discovery and vaccine development efforts against a wide range of antigen targets. • LIBRA-seq: high-throughput mapping of BCR sequence to antigen specificity • Identified HIV- and influenza-specific B cells in two HIV-infected subjects • Predicted antigen reactivity for thousands of single B cells • Identified a previously unknown broadly neutralizing HIV antibody LIBRA-seq enables high-throughput mapping of B cell receptor sequence to antigen specificity at the single-cell level. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
5. Fc Glycan-Mediated Regulation of Placental Antibody Transfer.
- Author
-
Jennewein, Madeleine F., Goldfarb, Ilona, Dolatshahi, Sepideh, Cosgrove, Cormac, Noelette, Francesca J., Krykbaeva, Marina, Das, Jishnu, Sarkar, Aniruddh, Gorman, Matthew J., Fischinger, Stephanie, Boudreau, Carolyn M., Brown, Joelle, Cooperrider, Jennifer H., Aneja, Jasneet, Suscovich, Todd J., Graham, Barney S., Lauer, Georg M., Goetghebuer, Tessa, Marchant, Arnaud, and Lauffenburger, Douglas
- Subjects
- *
MATERNALLY acquired immunity , *KILLER cells , *IMMUNE complexes , *IMMUNOGLOBULINS , *IMMUNE system , *IMMUNE response - Abstract
Despite the worldwide success of vaccination, newborns remain vulnerable to infections. While neonatal vaccination has been hampered by maternal antibody-mediated dampening of immune responses, enhanced regulatory and tolerogenic mechanisms, and immune system immaturity, maternal pre-natal immunization aims to boost neonatal immunity via antibody transfer to the fetus. However, emerging data suggest that antibodies are not transferred equally across the placenta. To understand this, we used systems serology to define Fc features associated with antibody transfer. The Fc-profile of neonatal and maternal antibodies differed, skewed toward natural killer (NK) cell-activating antibodies. This selective transfer was linked to digalactosylated Fc-glycans that selectively bind FcRn and FCGR3A, resulting in transfer of antibodies able to efficiently leverage innate immune cells present at birth. Given emerging data that vaccination may direct antibody glycosylation, our study provides insights for the development of next-generation maternal vaccines designed to elicit antibodies that will most effectively aid neonates. • NK cell-activating antibodies are selectively transferred across the placenta • Digalactosylated Fc glycans are preferentially transferred across the placenta • Digalactosylated antibodies bind more effectively to FcRn and FCGR3A • Although immature, neonatal NK cells are highly responsive to immune complexes Antibodies with a specific glycan modification and with the ability to activate NK cells are selectively transferred across the placenta to the neonate. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
6. Cross-Neutralizing and Protective Human Antibody Specificities to Poxvirus Infections.
- Author
-
Gilchuk, Iuliia, Gilchuk, Pavlo, Sapparapu, Gopal, Lampley, Rebecca, Singh, Vidisha, Kose, Nurgun, Blum, David L., Hughes, Laura J., Satheshkumar, Panayampalli S., Townsend, Michael B., Kondas, Ashley V., Reed, Zachary, Weiner, Zachary, Olson, Victoria A., Hammarlund, Erika, Raue, Hans-Peter, Slifka, Mark K., Slaughter, James C., Graham, Barney S., and Edwards, Kathryn M.
- Subjects
- *
POXVIRUS diseases , *ANTIBODY specificity , *CROSS reactions (Immunology) , *BIOTERRORISM , *VACCINIA diseases , *MONOCLONAL antibodies , *MONKEYPOX , *PREVENTION , *IMMUNOLOGY - Abstract
Summary Monkeypox (MPXV) and cowpox (CPXV) are emerging agents that cause severe human infections on an intermittent basis, and variola virus (VARV) has potential for use as an agent of bioterror. Vaccinia immune globulin (VIG) has been used therapeutically to treat severe orthopoxvirus infections but is in short supply. We generated a large panel of orthopoxvirus-specific human monoclonal antibodies (Abs) from immune subjects to investigate the molecular basis of broadly neutralizing antibody responses for diverse orthopoxviruses. Detailed analysis revealed the principal neutralizing antibody specificities that are cross-reactive for VACV, CPXV, MPXV, and VARV and that are determinants of protection in murine challenge models. Optimal protection following respiratory or systemic infection required a mixture of Abs that targeted several membrane proteins, including proteins on enveloped and mature virion forms of virus. This work reveals orthopoxvirus targets for human Abs that mediate cross-protective immunity and identifies new candidate Ab therapeutic mixtures to replace VIG. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
7. Protection from SARS-CoV-2 Delta one year after mRNA-1273 vaccination in rhesus macaques coincides with anamnestic antibody response in the lung.
- Author
-
Gagne M, Corbett KS, Flynn BJ, Foulds KE, Wagner DA, Andrew SF, Todd JM, Honeycutt CC, McCormick L, Nurmukhambetova ST, Davis-Gardner ME, Pessaint L, Bock KW, Nagata BM, Minai M, Werner AP, Moliva JI, Tucker C, Lorang CG, Zhao B, McCarthy E, Cook A, Dodson A, Teng IT, Mudvari P, Roberts-Torres J, Laboune F, Wang L, Goode A, Kar S, Boyoglu-Barnum S, Yang ES, Shi W, Ploquin A, Doria-Rose N, Carfi A, Mascola JR, Boritz EA, Edwards DK, Andersen H, Lewis MG, Suthar MS, Graham BS, Roederer M, Moore IN, Nason MC, Sullivan NJ, Douek DC, and Seder RA
- Abstract
mRNA-1273 vaccine efficacy against SARS-CoV-2 Delta wanes over time; however, there are limited data on the impact of durability of immune responses on protection. Here, we immunized rhesus macaques and assessed immune responses over 1 year in blood and upper and lower airways. Serum neutralizing titers to Delta were 280 and 34 reciprocal ID
50 at weeks 6 (peak) and 48 (challenge), respectively. Antibody-binding titers also decreased in bronchoalveolar lavage (BAL). Four days after Delta challenge, the virus was unculturable in BAL, and subgenomic RNA declined by ∼3-log10 compared with control animals. In nasal swabs, sgRNA was reduced by 1-log10 , and the virus remained culturable. Anamnestic antibodies (590-fold increased titer) but not T cell responses were detected in BAL by day 4 post-challenge. mRNA-1273-mediated protection in the lungs is durable but delayed and potentially dependent on anamnestic antibody responses. Rapid and sustained protection in upper and lower airways may eventually require a boost., Competing Interests: Declaration of interests K.S.C. and B.S.G. are inventors on US patent no. 10,960,070 B2 and International patent application no. WO/2018/081318 entitled “Prefusion Coronavirus Spike Proteins and Their Use”. K.S.C. and B.S.G. are inventors on US patent application no. 62/972,886 entitled “2019-nCoV Vaccine”. L.W., E.S.Y., W.S., J.R.M., M.R., N.J.S. and D.C.D are inventors on US patent application no. 63/147,419 entitled “Antibodies Targeting the Spike Protein of Coronaviruses”. L.P., A. Cook, A.D., A.G., S.K., H.A., and M.G.L. are employees of Bioqual. K.S.C., L.W., W.S., and B.S.G are inventors on multiple US patent applications entitled “Anti-Coronavirus Antibodies and Methods of Use”. A. Carfi and D.K.E. are employees of Moderna. M.S.S. serves on the scientific board of advisors for Moderna. The other authors declare no competing interests., (Copyright © 2021. Published by Elsevier Inc.)- Published
- 2022
- Full Text
- View/download PDF
8. In vitro and in vivo functions of SARS-CoV-2 infection-enhancing and neutralizing antibodies.
- Author
-
Li D, Edwards RJ, Manne K, Martinez DR, Schäfer A, Alam SM, Wiehe K, Lu X, Parks R, Sutherland LL, Oguin TH 3rd, McDanal C, Perez LG, Mansouri K, Gobeil SMC, Janowska K, Stalls V, Kopp M, Cai F, Lee E, Foulger A, Hernandez GE, Sanzone A, Tilahun K, Jiang C, Tse LV, Bock KW, Minai M, Nagata BM, Cronin K, Gee-Lai V, Deyton M, Barr M, Von Holle T, Macintyre AN, Stover E, Feldman J, Hauser BM, Caradonna TM, Scobey TD, Rountree W, Wang Y, Moody MA, Cain DW, DeMarco CT, Denny TN, Woods CW, Petzold EW, Schmidt AG, Teng IT, Zhou T, Kwong PD, Mascola JR, Graham BS, Moore IN, Seder R, Andersen H, Lewis MG, Montefiori DC, Sempowski GD, Baric RS, Acharya P, Haynes BF, and Saunders KO
- Subjects
- Animals, Antibodies, Viral immunology, Bronchoalveolar Lavage Fluid chemistry, COVID-19 pathology, COVID-19 virology, Cytokines metabolism, Female, Haplorhini, Humans, Lung pathology, Lung virology, Male, Mice, Mice, Inbred BALB C, Protein Domains, Receptors, IgG metabolism, SARS-CoV-2 isolation & purification, Spike Glycoprotein, Coronavirus chemistry, Viral Load, Virus Replication, Antibodies, Neutralizing immunology, SARS-CoV-2 physiology, Spike Glycoprotein, Coronavirus immunology
- Abstract
SARS-CoV-2-neutralizing antibodies (NAbs) protect against COVID-19. A concern regarding SARS-CoV-2 antibodies is whether they mediate disease enhancement. Here, we isolated NAbs against the receptor-binding domain (RBD) or the N-terminal domain (NTD) of SARS-CoV-2 spike from individuals with acute or convalescent SARS-CoV-2 or a history of SARS-CoV infection. Cryo-electron microscopy of RBD and NTD antibodies demonstrated function-specific modes of binding. Select RBD NAbs also demonstrated Fc receptor-γ (FcγR)-mediated enhancement of virus infection in vitro, while five non-neutralizing NTD antibodies mediated FcγR-independent in vitro infection enhancement. However, both types of infection-enhancing antibodies protected from SARS-CoV-2 replication in monkeys and mice. Three of 46 monkeys infused with enhancing antibodies had higher lung inflammation scores compared to controls. One monkey had alveolar edema and elevated bronchoalveolar lavage inflammatory cytokines. Thus, while in vitro antibody-enhanced infection does not necessarily herald enhanced infection in vivo, increased lung inflammation can rarely occur in SARS-CoV-2 antibody-infused macaques., Competing Interests: Declaration of interests B.F.H., G.D.S., K.O.S., R.P., D.L., P.A., and X.L. have applied for patents concerning SARS-CoV-2 Abs that are related to this work. All other authors declare no conflict of interest., (Copyright © 2021 Elsevier Inc. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
9. Vaccine-Induced Antibodies that Neutralize Group 1 and Group 2 Influenza A Viruses.
- Author
-
Joyce MG, Wheatley AK, Thomas PV, Chuang GY, Soto C, Bailer RT, Druz A, Georgiev IS, Gillespie RA, Kanekiyo M, Kong WP, Leung K, Narpala SN, Prabhakaran MS, Yang ES, Zhang B, Zhang Y, Asokan M, Boyington JC, Bylund T, Darko S, Lees CR, Ransier A, Shen CH, Wang L, Whittle JR, Wu X, Yassine HM, Santos C, Matsuoka Y, Tsybovsky Y, Baxa U, Mullikin JC, Subbarao K, Douek DC, Graham BS, Koup RA, Ledgerwood JE, Roederer M, Shapiro L, Kwong PD, Mascola JR, and McDermott AB
- Subjects
- Adult, Amino Acid Sequence, Antibodies, Neutralizing chemistry, Antibodies, Neutralizing genetics, Antibodies, Viral chemistry, Antibodies, Viral genetics, B-Lymphocytes immunology, Epitopes, B-Lymphocyte, Female, Gene Rearrangement, B-Lymphocyte, Heavy Chain, Humans, Immunologic Memory, Influenza A Virus, H5N1 Subtype immunology, Male, Middle Aged, Models, Molecular, Protein Structure, Tertiary, Structure-Activity Relationship, Young Adult, Antibodies, Neutralizing immunology, Antibodies, Viral immunology, Influenza A virus immunology, Influenza Vaccines immunology
- Abstract
Antibodies capable of neutralizing divergent influenza A viruses could form the basis of a universal vaccine. Here, from subjects enrolled in an H5N1 DNA/MIV-prime-boost influenza vaccine trial, we sorted hemagglutinin cross-reactive memory B cells and identified three antibody classes, each capable of neutralizing diverse subtypes of group 1 and group 2 influenza A viruses. Co-crystal structures with hemagglutinin revealed that each class utilized characteristic germline genes and convergent sequence motifs to recognize overlapping epitopes in the hemagglutinin stem. All six analyzed subjects had sequences from at least one multidonor class, and-in half the subjects-multidonor-class sequences were recovered from >40% of cross-reactive B cells. By contrast, these multidonor-class sequences were rare in published antibody datasets. Vaccination with a divergent hemagglutinin can thus increase the frequency of B cells encoding broad influenza A-neutralizing antibodies. We propose the sequence signature-quantified prevalence of these B cells as a metric to guide universal influenza A immunization strategies., (Published by Elsevier Inc.)
- Published
- 2016
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.